151 related articles for article (PubMed ID: 33063147)
21. Radiomics Analysis of
Yoo J; Lee J; Cheon M; Kim H; Choi YS; Pyo H; Ahn MJ; Choi JY
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046673
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
23.
Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
[TBL] [Abstract][Full Text] [Related]
24. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study.
Im HJ; Zhang Y; Wu H; Wu J; Daw NC; Navid F; Shulkin BL; Cho SY
Radiology; 2018 Apr; 287(1):303-312. PubMed ID: 29357275
[TBL] [Abstract][Full Text] [Related]
26. Prospective Study of Serial
Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM
J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233
[TBL] [Abstract][Full Text] [Related]
27. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.
Byun BH; Kong CB; Lim I; Kim BI; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1553-62. PubMed ID: 24652233
[TBL] [Abstract][Full Text] [Related]
28. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
29. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N
Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378
[TBL] [Abstract][Full Text] [Related]
30. Intra-tumor metabolic heterogeneity of gastric cancer on
Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
[TBL] [Abstract][Full Text] [Related]
31. Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Using Convolutional Neural Network of Tumor Center
Kim J; Jeong SY; Kim BC; Byun BH; Lim I; Kong CB; Song WS; Lim SM; Woo SK
Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829324
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.
Herrmann K; Benz MR; Czernin J; Allen-Auerbach MS; Tap WD; Dry SM; Schuster T; Eckardt JJ; Phelps ME; Weber WA; Eilber FC
Clin Cancer Res; 2012 Apr; 18(7):2024-31. PubMed ID: 22338012
[TBL] [Abstract][Full Text] [Related]
34. PET/CT with Fluorodeoxyglucose During Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
Travaini LL; Zampino MG; Colandrea M; Ferrari ME; Gilardi L; Leonardi MC; Santoro L; Orecchia R; Grana CM
Ecancermedicalscience; 2016; 10():629. PubMed ID: 27110285
[TBL] [Abstract][Full Text] [Related]
35. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
36. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of third treatment week as temporal window for assessing responsiveness on repeated FDG-PET-CT scans in Non-Small Cell Lung Cancer patients.
Lazzeroni M; Uhrdin J; Carvalho S; van Elmpt W; Lambin P; Dasu A; Wersäll P; Toma-Dasu I
Phys Med; 2018 Feb; 46():45-51. PubMed ID: 29519408
[TBL] [Abstract][Full Text] [Related]
38. The Role of (18)F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma.
Chang KJ; Lim I; Park JY; Jo AR; Kong CB; Song WS; Jo WH; Lee SY; Koh JS; Kim BI; Choi CW; Lim SM
Nucl Med Mol Imaging; 2015 Mar; 49(1):33-41. PubMed ID: 25774236
[TBL] [Abstract][Full Text] [Related]
39. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.
Denecke T; Hundsdörfer P; Misch D; Steffen IG; Schönberger S; Furth C; Plotkin M; Ruf J; Hautzel H; Stöver B; Kluge R; Bierbach U; Otto S; Beck JF; Franzius C; Henze G; Amthauer H
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1842-53. PubMed ID: 20505933
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment tumor SUV
Ha SC; Oh JS; Roh JL; Moon H; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):33-40. PubMed ID: 27448574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
